Delivery Order SPE2DB24D1104-SPE2DB25FYFT8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $33,203.38 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count units). This competitive, firm fixed-price delivery order was executed on August 21, 2025, with an ultimate completion date of August 22, 2025. The contract does not carry a set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a $3,611.49 delivery order to AmerisourceBergen Drug Corp for CellCept 500 mg tablets (100-count) under a firm fixed-price contract. The award was issued on September 15, 2025, with an ultimate completion date of September 16, 2025, and represents a non-competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $12,986.33 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500 count) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed price, competitively awarded delivery order represents a single pharmaceutical product shipment with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100 count) on September 8, 2025, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price delivery order has a ceiling value of $27,735.62 and carries no set-aside designation. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a $13,249.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count units). The contract was competitively awarded without set-aside designation and is set for completion by September 16, 2025. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $35,063.75 to AmerisourceBergen Drug Corp for 100 tablets of CellCept 500 mg, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a delivery order under a larger contract vehicle. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100-count units) valued at $7,854.18. The award was made on May 6, 2025, with an ultimate completion date of May 7, 2025, under a firm fixed-price delivery order arrangement. The contract was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,545.90 to AmerisourceBergen Drug Corp for 100 tablets of CellCept 500 mg on September 3, 2025, with an ultimate completion date of September 4, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through its Corporate Office division as part of ongoing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100-count units) with a ceiling value of $9,754.64. This firm fixed-price delivery order, issued on August 26, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion and extending through December 2026. The award was competitively awarded with no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for CellCept 500 mg tablets (500-count packages) valued at $12,029.30 under a firm fixed-price contract type. This award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion pharmaceutical supply vehicle running through December 2026. CellCept (mycophenolate mofetil) is an...
- SPE2DB24D1104Indefinite Delivery Contract
- SPE2DB24D1104-SPE2DB25FYFT8Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $31,318.38 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100-count units) under a firm fixed price contract. The award, issued on September 11, 2025, with an ultimate completion date of September 12, 2025, represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the place of performance for this pharmaceutical supply transaction, leveraging its extensive capabilities as a major healthcare solutions provider for federal medical procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026 that enables the company to supply a comprehensive range of pharmaceuticals and medical supplies to support military healthcare programs worldwide. CellCept, an immunosuppressant medication, represents part of the company's portfolio of specialty medications and brand-name drugs delivered through this flexible contracting vehicle, which supports the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.3k | 9/11/25 |